Log In
BCIQ
Print this Print this
 

bromfenac (BromSite) (ISV-303)

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
DescriptionLow-dose bromfenac, an NSAID, delivered via InSite's DuraSite sustained delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat inflammation and eye pain; Treat postoperative ocular inflammation and prevent pain during cataract surgery
Regulatory Designation
PartnerVISUfarma B.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$117.3M

$61.0M

$13.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today